Medicines and Medical Devices Act 2021
2021 c. 3An Act to make provision about a Commissioner for Patient Safety in relation to human medicines and medical devices; confer power to amend or supplement the law relating to human medicines, veterinary medicines and medical devices; make provision about the enforcement of regulations, and the protection of health and safety, in relation to medical devices; and for connected purposes.
Enacted[11th February 2021]
Be it enacted by the Queen's most Excellent Majesty, by and with the advice and consent of the Lords Spiritual and Temporal, and Commons, in this present Parliament assembled, and by the authority of the same, as follows:—
PART 1 The Commissioner for Patient Safety¶
1 Establishment and core duties etc¶
PART 2 Human medicines¶
CHAPTER 1 Regulations: general¶
2 Power to make regulations about human medicines¶
3 Manufacture, marketing and supply¶
4 Falsified medicines¶
5 Clinical trials¶
I16 Fees, offences, powers of inspectors¶
7 Emergencies¶
CHAPTER 1A Regulations: information systems¶
7A Information systems¶
- “data protection legislation” has the meaning given by section 3(9) of the Data Protection Act 2018;
- “health service”, in relation to Wales, has the meaning given by section 206(1) of the National Health Service (Wales) Act 2006;
- “human medicine” has the same meaning as in Part 2 (see section 9);
- “individual health information” means information (however recorded) which relates to—
- the physical or mental health or condition of an individual,
- the diagnosis of an individual’s condition, or
- an individual’s care or treatment,
- “specified” means specified in regulations under subsection (1).
7B Offence of disclosing information¶
CHAPTER 2 International agreements: disclosure of information¶
8 Disclosure of information in accordance with international agreements¶
- “commercially sensitive information” means commercial information whose disclosure the relevant authority thinks might significantly harm the legitimate business interests of the undertaking to which it relates;
- “data protection legislation” has the meaning given by section 3(9) of the Data Protection Act 2018;
- “patient information” means information (however recorded) which—
- relates to—
- the physical or mental health or condition of an individual,
- the diagnosis of an individual's condition, or
- an individual's care or treatment,
or is (to any extent) derived directly or indirectly from information relating to any of those matters, and - identifies the individual or enables the individual to be identified (whether by itself or in combination with other information);
- “relevant authority” means—
- the Secretary of State, or
- the Department of Health in Northern Ireland;
- “relevant person” means—
- the government of a country or territory outside the United Kingdom;
- a person who exercises functions on behalf of such a government;
- any other person who exercises functions or provides services relating to human medicines in a country or territory outside the United Kingdom;
- an international organisation that exercises functions or provides services relating to human medicines.
CHAPTER 3 Interpretation¶
9 Interpretation of Part 2¶
In this Part—- “active substance” has the meaning given by regulation 8 of the Human Medicines Regulations 2012 (S.I. 2012/1916);
- “appropriate authority” has the meaning given by section 2(6);
- “clinical trial” has the meaning given by regulation 2(1) of the Medicines for Human Use (Clinical Trials) Regulations 2004 (S.I. 2004/1031);
- “EU Clinical Trials Regulation” has the meaning given by section 5(2);
- “falsified human medicine” means a falsified medicinal product within the meaning given by regulation 8 of the Human Medicines Regulations 2012;
- “human medicine” means a medicinal product within the meaning given by regulation 2 of the Human Medicines Regulations 2012;
- “human medicines provision” has the meaning given by section 6(4);
- “law relating to human medicines” means—
- sections 10 and 15, and Part 4, and section 131 of the Medicines Act 1968 (which make provision relating to pharmacies),
- the Human Medicines Regulations 2012,
- the Medicines for Human Use (Clinical Trials) Regulations 2004, and
- the Medicines (Products for Human Use) (Fees) Regulations 2016 (S.I. 2016/190);
- “manufacture” includes assembly;
- “marketing authorisation” means an authorisation to market a human medicine in the United Kingdom;
- “pharmacy business” means a business (other than a professional practice carried on by a doctor or dentist) which consists of or includes the sale of medicinal products that are not subject to general sale;
- “supplying” includes administering within the meaning given by regulation 8 of the Human Medicines Regulations 2012 (and related expressions are to be read accordingly).
PART 3 Veterinary medicines¶
CHAPTER 1 Regulations¶
10 Power to make regulations about veterinary medicines¶
11 Manufacture, marketing, supply and field trials¶
12 Fees, offences, powers of inspectors, costs¶
CHAPTER 2 International agreements: disclosure of information¶
13 Disclosure of information in accordance with international agreements¶
- “commercially sensitive information” means commercial information whose disclosure the relevant authority thinks might significantly harm the legitimate business interests of the undertaking to which it relates;
- “data protection legislation” has the meaning given by section 3(9) of the Data Protection Act 2018;
- “relevant authority” means—
- the Secretary of State, or
- the Department of Agriculture, Environment and Rural Affairs in Northern Ireland;
- “relevant person” means—
- the government of a country or territory outside the United Kingdom;
- a person who exercises functions on behalf of such a government;
- any other person who exercises functions or provides services relating to veterinary medicines in a country or territory outside the United Kingdom;
- an international organisation that exercises functions or provides services relating to veterinary medicines.
CHAPTER 3 Interpretation etc¶
14 Interpretation of Part 3 and supplementary provision¶
- “active substance” means any substance or mixture of substances intended to be used in the manufacture of a veterinary medicine that, when used in its production, becomes an active ingredient of that medicine;
- “appropriate authority” has the meaning given by section 10(6);
- “manufacture” includes assembly;
- “marketing authorisation” means an authorisation to market a veterinary medicine in the United Kingdom;
- “veterinary medicine” means a veterinary medicinal product within the meaning given by regulation 2 of the Veterinary Medicines Regulations 2013 (S.I. 2013/2033).
PART 4 Medical devices¶
CHAPTER 1 Regulations: general¶
15 Power to make regulations about medical devices¶
16 Manufacture, marketing and supply¶
I217 Fees, information, offences¶
18 Emergencies¶
CHAPTER 2 Regulations: information systems, advisory committee¶
19 Information systems¶
20 Advisory committee¶
CHAPTER 3 Enforcement¶
Enforcement notices¶
I421 Compliance notices¶
I522 Suspension notices¶
I623 Safety notices¶
I724 Information notices¶
I825 Applications to set notices aside etc¶
I926 Compensation¶
I1027 Further appeals¶
Offences¶
I1128 Offences¶
I1229 Defence of due diligence¶
I1330 Offences by bodies corporate¶
Civil sanctions¶
31 Civil sanctions¶
Schedule 2 makes provision for and relating to civil sanctions in relation to the commission of offences to do with medical devices.Forfeiture¶
I1432 Forfeiture of medical devices¶
I1533 Appeals against forfeiture decisions¶
Recovery of expenses of enforcement¶
I1634 Recovery of expenses of enforcement¶
Recall of medical device by enforcement authority¶
I1735 Recall of medical device by enforcement authority¶
Power of officer of Revenue and Customs to detain medical device¶
I1836 Power of officer of Revenue and Customs to detain medical device¶
I1937 Offence of obstructing an officer of Revenue and Customs¶
Civil proceedings¶
I2038 Civil proceedings¶
CHAPTER 4 Disclosure of information and consequential etc provision¶
Disclosure of information¶
I2139 Disclosure of information¶
- “commercially sensitive information” means commercial information whose disclosure the Secretary of State thinks might significantly harm the legitimate business interests of the undertaking to which it relates;
- “patient information” means information (however recorded) which—
- relates to—
- the physical or mental health or condition of an individual,
- the diagnosis of an individual's condition, or
- an individual's care or treatment,
or is (to any extent) derived directly or indirectly from information relating to any of those matters, and - identifies the individual or enables the individual to be identified (whether by itself or in combination with other information);
- “relevant person” means—
- the government of a country or territory outside the United Kingdom;
- a person who exercises functions on behalf of such a government;
- any other person who exercises functions or provides services relating to medical devices in a country or territory outside the United Kingdom;
- an international organisation that exercises functions or provides services relating to medical devices.
I2240 Offences relating to information¶
Consequential etc provision¶
41 Consequential and supplementary provision¶
;
.
;
;
;
CHAPTER 5 Interpretation of Part 4¶
42 Interpretation of Part 4¶
- the “appropriate appeals court” means—
- in England and Wales, the Crown Court;
- in Scotland, the Sheriff Appeal Court;
- in Northern Ireland, a county court;
- the “appropriate lower court” means—
- in England and Wales, a magistrates' court;
- in Scotland, the sheriff;
- in Northern Ireland, a court of summary jurisdiction;
- “compliance notice” has the meaning given by section 21(2);
- “data protection legislation” has the meaning given by section 3(9) of the Data Protection Act 2018;
- the “enforcement authority” means—
- in relation to medical devices which are ordinarily intended for private use or consumption—
- a local weights and measures authority in Great Britain or a district council in Northern Ireland, or
- the Secretary of State, or
- in relation to other medical devices, the Secretary of State;
- “EU Medical Devices Regulations” means—
- Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC, and
- Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU;
- “forfeiture order” has the meaning given by section 32(1);
- “information notice” has the meaning given by section 24(2);
- “manufacture” includes assembly;
- “manufacturer” means any person who is a manufacturer for the purposes of any provision in—
- the Medical Devices Regulations 2002 (S.I. 2002/618), or
- the EU Medical Devices Regulations;
- “medical device” includes—
- medical devices to which the Medical Devices Regulations 2002 apply, and
- devices to which the EU Medical Devices Regulations apply;
- “medical devices provision”—
- in Chapter 1, has the meaning given by section 17(2), and
- in Chapter 3, has the meaning given by section 21(1A);
- “relevant requirements” has the meaning given by section 16(1)(a);
- “safety notice” has the meaning given by section 23(1);
- “suspension notice” has the meaning given by section 22(2).
PART 5 Regulations under Parts 1, 2, 3 and 4¶
43 Power to make consequential etc provision¶
44 Scope of powers of Northern Ireland departments¶
No provision may be made by a Northern Ireland department acting alone in regulations under section 2(1) , 7A(1) or 10(1) unless the provision, if it were contained in an Act of the Northern Ireland Assembly—45 Consultation¶
46 Reporting requirements¶
- “appropriate legislature” means—
- in relation to a report of the Secretary of State, Parliament;
- in relation to a report of a Northern Ireland department, the Northern Ireland Assembly;
- “relevant authority” means—
- in relation to regulations made under section 2(1) , 7A(1) or 10(1) by the Secretary of State (whether acting alone or jointly with a Northern Ireland department), the Secretary of State;
- in relation to regulations made under section 2(1) , 7A(1) or 10(1) by a Northern Ireland department (whether acting alone or jointly with the Secretary of State), the Northern Ireland department;
- in relation to regulations made under section 15(1) or 19(1), the Secretary of State.
47 Procedure¶
| If the regulations contain provision made in reliance on | the regulations are subject to |
|---|---|
| section 6(1)(a) | the negative procedure |
| section 12(1)(a) | the negative procedure |
| section 17(1)(a) | the negative procedure |
| paragraph 9 of Schedule 2 | the negative procedure |
| section 7 | |
| section 18 | |
| any other provision of Part 1, 2, 3 or 4 | the draft affirmative procedure |
PART 6 Report on operation of medicines and medical devices legislation¶
48 Report on operation of medicines and medical devices legislation¶
- “medicines and medical devices legislation” means—
- the law relating to human medicines within the meaning of section 9 (interpretation);
- the Veterinary Medicines Regulations 2013 (S.I. 2013/2033);
- the Medical Devices Regulations 2002 (S.I. 2002/618);
- Parts 2 to 5 of this Act;
- regulations made under those Parts;
- “Parliamentary Committee” means a committee of the House of Commons or of the House of Lords or a joint committee of both Houses;
- “relevant period” means the period of 5 years beginning with the day on which this Act is passed.
PART 7 Extent, commencement and short title¶
49 Extent¶
This Act extends to England and Wales, Scotland and Northern Ireland.50 Commencement¶
51 Transitional etc provision in connection with commencement¶
52 Short title¶
This Act may be cited as the Medicines and Medical Devices Act 2021.SCHEDULES
SCHEDULE 1 ¶
Further provision about the Commissioner for Patient Safety
Section 1
Principles relating to core duties¶
Involvement of patients¶
Supplementary functions and information¶
- “data protection legislation” has the meaning given by section 3(9) of the Data Protection Act 2018;
- “health care” means all forms of health care provided for individuals, whether relating to physical or mental health, and including ancillary care;
- “relevant person” means—
- a person who exercises functions of a public nature, relating to medicines or medical devices, so far as those functions are exercisable in relation to England;
- any other person who, in the course of providing health care, provides services relating to medicines or medical devices in relation to England.
Individual cases¶
Amendments to primary legislation¶
.
Regulations about appointment and operation¶
SCHEDULE 2 ¶
Medical devices: civil sanctions
Section 31
PART 1 Monetary penalties¶
Imposition of monetary penalty¶
Notices, representations and appeals etc¶
Information to be included in notices under paragraph 2¶
Monetary penalties: criminal proceedings and conviction¶
PART 2 Enforcement undertakings¶
PART 3 Enforcement costs recovery notices¶
Imposition of enforcement costs recovery notices¶
Information to be included in enforcement costs recovery notices¶
Appeals¶
PART 4 Power to make supplementary provision etc by regulations¶
Supplementary regulations: general¶
Monetary penalties and costs¶
Enforcement undertakings¶
Appeals¶
PART 5 General and supplemental¶
Guidance as to enforcement¶
Pre-commencement consultation¶
Reports on use of civil sanctions¶
Disclosure of information¶
PART 6 Interpretation¶
- “enforcement costs recovery notice” has the meaning given by paragraph 6(2);
- “enforcement undertaking” has the meaning given by paragraph 5(1)(b);
- “monetary penalty” has the meaning given by paragraph 1(2);
- “supplementary regulations” has the meaning given by paragraph 9.
SCHEDULE 3 ¶
Offence of breaching provisions in the Medical Devices Regulations 2002
Section 41
PART 1 Offence¶
PART 2 Provisions¶
Footnotes
- I1S. 6(4) in force at 11.2.2021 see s. 50(1)(c)
- I2S. 17(2) in force at 11.2.2021 see s. 50(1)(g)
- I3S. 41(1)-(8) in force at 26.5.2021 by S.I. 2021/610, reg. 2(c) (with reg. 3)
- I4S. 21 in force at 26.5.2021 by S.I. 2021/610, reg. 2(a)
- I5S. 22 in force at 26.5.2021 by S.I. 2021/610, reg. 2(a)
- I6S. 23 in force at 26.5.2021 by S.I. 2021/610, reg. 2(a)
- I7S. 24 in force at 26.5.2021 by S.I. 2021/610, reg. 2(a)
- I8S. 25 in force at 26.5.2021 by S.I. 2021/610, reg. 2(a)
- I9S. 26 in force at 26.5.2021 by S.I. 2021/610, reg. 2(a)
- I10S. 27 in force at 26.5.2021 by S.I. 2021/610, reg. 2(a)
- I11S. 28 in force at 26.5.2021 by S.I. 2021/610, reg. 2(a)
- I12S. 29 in force at 26.5.2021 by S.I. 2021/610, reg. 2(a)
- I13S. 30 in force at 26.5.2021 by S.I. 2021/610, reg. 2(a)
- I14S. 32 in force at 26.5.2021 by S.I. 2021/610, reg. 2(a)
- I15S. 33 in force at 26.5.2021 by S.I. 2021/610, reg. 2(a)
- I16S. 34 in force at 26.5.2021 by S.I. 2021/610, reg. 2(a)
- I17S. 35 in force at 26.5.2021 by S.I. 2021/610, reg. 2(a)
- I18S. 36 in force at 26.5.2021 by S.I. 2021/610, reg. 2(a)
- I19S. 37 in force at 26.5.2021 by S.I. 2021/610, reg. 2(a)
- I20S. 38 in force at 26.5.2021 by S.I. 2021/610, reg. 2(a)
- I21S. 39 in force at 26.5.2021 by S.I. 2021/610, reg. 2(b)
- I22S. 40 in force at 26.5.2021 by S.I. 2021/610, reg. 2(b)
- F1Words in s. 17(2) substituted (27.7.2021) by The Medical Devices (Northern Ireland Protocol) Regulations 2021 (S.I. 2021/905), regs. 1(2), 28(2)
- F2S. 21(1A) inserted (27.7.2021) by The Medical Devices (Northern Ireland Protocol) Regulations 2021 (S.I. 2021/905), regs. 1(2), 28(3)
- F3Words in s. 34(1)(a) substituted (27.7.2021) by The Medical Devices (Northern Ireland Protocol) Regulations 2021 (S.I. 2021/905), regs. 1(2), 28(4)
- F4Word in s. 39(10)(a) omitted (27.7.2021) by virtue of The Medical Devices (Northern Ireland Protocol) Regulations 2021 (S.I. 2021/905), regs. 1(2), 28(5)(a)
- F5S. 39(10)(c) and word inserted (27.7.2021) by The Medical Devices (Northern Ireland Protocol) Regulations 2021 (S.I. 2021/905), regs. 1(2), 28(5)(b)
- F6Words in s. 42(2) substituted (27.7.2021) by The Medical Devices (Northern Ireland Protocol) Regulations 2021 (S.I. 2021/905), regs. 1(2), 28(6)(a)
- F7Words in s. 42(2) substituted (27.7.2021) by The Medical Devices (Northern Ireland Protocol) Regulations 2021 (S.I. 2021/905), regs. 1(2), 28(6)(b)
- F8Word in Sch. 2 para. 1(1)(a) omitted (27.7.2021) by virtue of The Medical Devices (Northern Ireland Protocol) Regulations 2021 (S.I. 2021/905), regs. 1(2), 28(7)(a)(i)
- F9Sch. 2 para. 1(1)(c) and word inserted (27.7.2021) by The Medical Devices (Northern Ireland Protocol) Regulations 2021 (S.I. 2021/905), regs. 1(2), 28(7)(a)(ii)
- F10Words in Sch. 2 para. 4(1)(a) substituted (27.7.2021) by The Medical Devices (Northern Ireland Protocol) Regulations 2021 (S.I. 2021/905), regs. 1(2), 28(7)(b)(i)
- F11Words in Sch. 2 para. 4(1)(b) substituted (27.7.2021) by The Medical Devices (Northern Ireland Protocol) Regulations 2021 (S.I. 2021/905), regs. 1(2), 28(7)(b)(ii)
- F12Words in Sch. 2 para. 4(2) substituted (27.7.2021) by The Medical Devices (Northern Ireland Protocol) Regulations 2021 (S.I. 2021/905), regs. 1(2), 28(7)(b)(iii)
- F13Words in Sch. 2 para. 5(1)(a) substituted (27.7.2021) by The Medical Devices (Northern Ireland Protocol) Regulations 2021 (S.I. 2021/905), regs. 1(2), 28(7)(c)(i)
- F14Words in Sch. 2 para. 5(2)(a) substituted (27.7.2021) by The Medical Devices (Northern Ireland Protocol) Regulations 2021 (S.I. 2021/905), regs. 1(2), 28(7)(c)(ii)
- F15Words in Sch. 2 para. 13(1)(a) substituted (27.7.2021) by The Medical Devices (Northern Ireland Protocol) Regulations 2021 (S.I. 2021/905), regs. 1(2), 28(7)(d)
- F16Pt. 2 Ch. 1 heading substituted (1.7.2022) by Health and Care Act 2022 (c. 31), ss. 101(2), 186(6); S.I. 2022/734, reg. 2(a), Sch. (with regs. 13, 29, 30)
- F17Pt. 2 Ch. 1A inserted (1.7.2022) by Health and Care Act 2022 (c. 31), ss. 101(3), 186(6); S.I. 2022/734, reg. 2(a), Sch. (with regs. 13, 29, 30)
- F18Words in s. 19(6)(b) substituted (1.7.2022) by Health and Care Act 2022 (c. 31), ss. 101(4)(a)(i), 186(6); S.I. 2022/734, reg. 2(a), Sch. (with regs. 13, 29, 30)
- F19Words in s. 19(6)(c) substituted (1.7.2022) by Health and Care Act 2022 (c. 31), ss. 101(4)(a)(ii), 186(6); S.I. 2022/734, reg. 2(a), Sch. (with regs. 13, 29, 30)
- F20S. 19(7A) inserted (1.7.2022) by Health and Care Act 2022 (c. 31), ss. 101(4)(b), 186(6); S.I. 2022/734, reg. 2(a), Sch. (with regs. 13, 29, 30)
- F21Words in s. 43(1) substituted (1.7.2022) by Health and Care Act 2022 (c. 31), ss. 101(5)(a), 186(6); S.I. 2022/734, reg. 2(a), Sch. (with regs. 13, 29, 30)
- F22S. 43(3) inserted (1.7.2022) by Health and Care Act 2022 (c. 31), ss. 101(5)(b), 186(6); S.I. 2022/734, reg. 2(a), Sch. (with regs. 13, 29, 30)
- F23Word in s. 44 inserted (1.7.2022) by Health and Care Act 2022 (c. 31), ss. 101(6), 186(6); S.I. 2022/734, reg. 2(a), Sch. (with regs. 13, 29, 30)
- F24S. 45(1A) inserted (1.7.2022) by Health and Care Act 2022 (c. 31), ss. 101(7)(a), 186(6); S.I. 2022/734, reg. 2(a), Sch. (with regs. 13, 29, 30)
- F25S. 45(6)(a)(aa) substituted for s. 45(6)(a) (1.7.2022) by Health and Care Act 2022 (c. 31), ss. 101(7)(b), 186(6); S.I. 2022/734, reg. 2(a), Sch. (with regs. 13, 29, 30)
- F26Word in s. 46(1) inserted (1.7.2022) by Health and Care Act 2022 (c. 31), ss. 101(8)(a), 186(6); S.I. 2022/734, reg. 2(a), Sch. (with regs. 13, 29, 30)
- F27Word in s. 46(3)(b) inserted (1.7.2022) by Health and Care Act 2022 (c. 31), ss. 101(8)(a), 186(6); S.I. 2022/734, reg. 2(a), Sch. (with regs. 13, 29, 30)
- F28Word in s. 46(4)(a) inserted (1.7.2022) by Health and Care Act 2022 (c. 31), ss. 101(8)(a), 186(6); S.I. 2022/734, reg. 2(a), Sch. (with regs. 13, 29, 30)
- F29Word in s. 46(5) inserted (1.7.2022) by Health and Care Act 2022 (c. 31), ss. 101(8)(b), 186(6); S.I. 2022/734, reg. 2(a), Sch. (with regs. 13, 29, 30)
- F30Word in s. 47(2) inserted (1.7.2022) by Health and Care Act 2022 (c. 31), ss. 101(9), 186(6); S.I. 2022/734, reg. 2(a), Sch. (with regs. 13, 29, 30)
- F31Words in s. 7A(1) substituted (1.2.2023) by The Health and Social Care Information Centre (Transfer of Functions, Abolition and Transitional Provisions) Regulations 2023 (S.I. 2023/98), reg. 1(2), Sch. para. 21(2)(a) (with reg. 3)
- F32Words in s. 7A(2)-(4) substituted (1.2.2023) by The Health and Social Care Information Centre (Transfer of Functions, Abolition and Transitional Provisions) Regulations 2023 (S.I. 2023/98), reg. 1(2), Sch. para. 21(2)(b) (with reg. 3)
- F33Words in s. 7A(6) substituted (1.2.2023) by The Health and Social Care Information Centre (Transfer of Functions, Abolition and Transitional Provisions) Regulations 2023 (S.I. 2023/98), reg. 1(2), Sch. para. 21(2)(b) (with reg. 3)
- F34Words in s. 7A(8)-(11) substituted (1.2.2023) by The Health and Social Care Information Centre (Transfer of Functions, Abolition and Transitional Provisions) Regulations 2023 (S.I. 2023/98), reg. 1(2), Sch. para. 21(2)(b) (with reg. 3)
- F35Words in s. 19(1) substituted (1.2.2023) by The Health and Social Care Information Centre (Transfer of Functions, Abolition and Transitional Provisions) Regulations 2023 (S.I. 2023/98), reg. 1(2), Sch. para. 21(3)(a) (with reg. 3)
- F36Words in s. 19(2) substituted (1.2.2023) by The Health and Social Care Information Centre (Transfer of Functions, Abolition and Transitional Provisions) Regulations 2023 (S.I. 2023/98), reg. 1(2), Sch. para. 21(3)(b) (with reg. 3)
- F37Words in s. 19(3) substituted (1.2.2023) by The Health and Social Care Information Centre (Transfer of Functions, Abolition and Transitional Provisions) Regulations 2023 (S.I. 2023/98), reg. 1(2), Sch. para. 21(3)(b) (with reg. 3)
- F38Words in s. 19(6) substituted (1.2.2023) by The Health and Social Care Information Centre (Transfer of Functions, Abolition and Transitional Provisions) Regulations 2023 (S.I. 2023/98), reg. 1(2), Sch. para. 21(3)(b) (with reg. 3)
- F39Words in s. 43(3) substituted (1.2.2023) by The Health and Social Care Information Centre (Transfer of Functions, Abolition and Transitional Provisions) Regulations 2023 (S.I. 2023/98), reg. 1(2), Sch. para. 21(4) (with reg. 3)
- F40S. 21(1A)(d) substituted (21.3.2024) by The Medical Devices (In Vitro Diagnostic Devices etc.) (Amendment) Regulations 2024 (S.I. 2024/221), regs. 1(2), 6
- F41Words in s. 42(2) substituted (21.3.2024) by The Medical Devices (In Vitro Diagnostic Devices etc.) (Amendment) Regulations 2024 (S.I. 2024/221), regs. 1(2), 7